Abstract
Familial medullary thyroid carcinoma (FMTC) is an autosomal dominant inherited disease, characterized by germ-line mutations in the RET proto-oncogene, mainly in exons 10 and 11, but also in exons 13, 14 and 15. Recently, mutations in exons 8 and 16 associated with FMTC were also described. In the herein presented study, single strand conformation polymorphism (SSCP) method for rapid screening of mutations in the RET proto-oncogene and fluorescent sequencing method were used. In one Czech family with FMTC, we have identified a novel missense point mutation of the RET proto-oncogene in exon 5, that results in substitution of arginine by glycine at codon 321 in the cadherin-like domain of ret protein. It seems that this mutation causes FMTC as no other mutation was found in the classical risk exons (10, 11, 13, 14, 15 and 16) of the RET proto-oncogene. The mutation cosegregates with medullary thyroid carcinoma (MTC) or C cell hyperplasia (CCH) in two patients; two other family members are mutation carriers without clinical signs of MTC so far. To improve the diagnosis of FMTC, analysis of exon 5 of the RET proto-oncogene should be considered in families with no identified classical RET mutations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000, 37: 817–27.
Ishizaka Y, Itoh F, Tahira T, et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989, 4: 1519–21.
Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276: 1575–9.
Mulligan LM, Marsh DJ, Robinson BG, et al. Genotypephenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238: 343–6.
Pigny P, Bauters C, Wemeau JL, et al. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 1999, 84: 1700–4.
Da Silva AM, Maciel RM, Da Silva MR, et al. A novel germline point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 5438–43.
Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 2002, 236: 570–5.
Feldman GL, Edmonds MW, Ainsworth PJ, et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG→ATG) mutation. Surgery 2000, 128: 93–8.
Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998, 83: 770–4.
Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM. Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 1997, 51: 81–5.
Eng C, Smith DP, Mulligan LM, et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10: 509–13.
Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2: 851–6.
Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogenes 1995, 10: 2415–9.
Hofstra RM, Fattoruso O, Quadro L, et al. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997, 82: 4176–8.
Lombardo F, Baudin E, Chiefari E, et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 2002, 87: 1674–80.
Jimenez C, Dang GT, Schultz PN, et al. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89: 3521–6.
Jindrichova S, Vcelak J, Vlcek P, Neradilova M, Nemec J, Bendlova B. Screening of six risk exons of the RET protooncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 2004, 183: 257–65.
Kusafuka T, Wang Y, Puri P. Mutation analysis of the RET, the endothelin-B receptor, and the endothelin-3 genes in sporadic cases of Hirschsprung’s disease. J Pediatr Surg 1997, 32: 501–4.
Brandi ML, Gagel RF, Angeli A, et al. Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 2001, 86: 5658–71.
Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001, 86: 1104–9.
Niccoli-Sire P, Murat A, Rohmer V, et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype–genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001, 86: 3746–53.
Kjaer S, Ibanez CF. Identification of a surface for binding to the GDNF-GFRa1 complex in the first cadherin-like domain of RET. J Biol Chem 2003, 278: 47898–904.
Kjaer S, Ibanez CF. Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET. Hum Mol Genet 2003, 12: 2133–44.
Shapiro L, Kwong PD, Fannon AM, Colman DR, Hendrickson WA. Considerations on the folding topology and evolutionary origin of cadherin domains. Proc Natl Acad Sci USA 1995, 92: 6793–7.
Anders J, Kjaer S, Ibanez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem 2001, 276: 35808–17.
Cosma MP, Cardone M, Carlomagno F, Colantuoni V. Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol Cell Biol 1998, 18: 3321–9.
Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995, 15: 1613–9.
Iwashita T, Murakami H, Asai N, Takahashi M. Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet 1996, 5: 1577–80.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dvorakova, S., Vaclavikova, E., Duskova, J. et al. Exon 5 of the RET proto-oncogene: A newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg. J Endocrinol Invest 28, 905–909 (2005). https://doi.org/10.1007/BF03345322
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345322